cd4 lymphocyte count

Summary

Summary: The number of CD4-POSITIVE T-LYMPHOCYTES per unit volume of BLOOD. Determination requires the use of a fluorescence-activated flow cytometer.

Top Publications

  1. ncbi CD4+ count-guided interruption of antiretroviral treatment
    W M El-Sadr
    Division of Infectious Diseases, Harlem Hospital Center and Columbia University, New York, NY 10037, USA
    N Engl J Med 355:2283-96. 2006
  2. pmc Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis
    Deborah Donnell
    Statistical Center for HIV AIDS Research and Prevention and the Vaccine and Infectious Disease Institute, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Lancet 375:2092-8. 2010
  3. pmc Early antiretroviral therapy and mortality among HIV-infected infants
    Avy Violari
    Perinatal HIV Research Unit, University of the Witwatersrand, Johannesburg, South Africa
    N Engl J Med 359:2233-44. 2008
  4. doi Effect of point-of-care CD4 cell count tests on retention of patients and rates of antiretroviral therapy initiation in primary health clinics: an observational cohort study
    Ilesh V Jani
    Instituto Nacional da Saúde, Maputo, Mozambique
    Lancet 378:1572-9. 2011
  5. pmc Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis
    Francois Xavier Blanc
    Pneumology Unit, Internal Medicine Department, Bicetre Hospital, Assistance Publique Hopitaux de Paris, Le Kremlin Bicetre, France
    N Engl J Med 365:1471-81. 2011
  6. pmc Timing of antiretroviral therapy for HIV-1 infection and tuberculosis
    Diane V Havlir
    University of California, San Francisco, 995 Potrero Ave, Bldg 80, Ward 84, San Francisco, CA 94110 2897, USA
    N Engl J Med 365:1482-91. 2011
  7. ncbi Decline in the AIDS and death rates in the EuroSIDA study: an observational study
    A Mocroft
    Royal Free Centre for HIV Medicine and Department of Primary Care and Population Sciences, Royal Free and University College Medical School, London, UK
    Lancet 362:22-9. 2003
  8. doi Effect of earlier initiation of antiretroviral treatment and increased treatment coverage on HIV-related mortality in China: a national observational cohort study
    Fujie Zhang
    Division of Treatment and Care, National Centre for AIDS STD Control and Prevention, Chinese Centre for Disease Control and Prevention, Beijing, China
    Lancet Infect Dis 11:516-24. 2011
  9. pmc Gender differences in survival among adult patients starting antiretroviral therapy in South Africa: a multicentre cohort study
    Morna Cornell
    Centre for Infectious Disease Epidemiology and Research, School of Public Health and Family Medicine, University of Cape Town, Cape Town, South Africa
    PLoS Med 9:e1001304. 2012
  10. pmc Second-line treatment in the Malawi antiretroviral programme: high early mortality, but good outcomes in survivors, despite extensive drug resistance at baseline
    M C Hosseinipour
    University of North Carolina Project, Lilongwe, Malawi
    HIV Med 11:510-8. 2010

Research Grants

  1. EVA MARIA CARMONA PORQUERA; Fiscal Year: 2016
  2. Small Animal Model of HIV Neuropathogenesis in the HAART Era
    Pietro P Sanna; Fiscal Year: 2012
  3. Longitudinal Studies of HIV-Associated Bacterial Pneumonia
    William N Rom; Fiscal Year: 2013
  4. Suppressors of cytokine signaling (SOCS) in HAART-treated HIV infection
    Maria C Villacres; Fiscal Year: 2010
  5. Alteration of circadian rhythm and sleep by HIV protein Tat
    Jian M Ding; Fiscal Year: 2012
  6. Non-CD4 Host defense against P. carinii Pneumonia
    Jay K Kolls; Fiscal Year: 2013
  7. CHIRATIDZO ELLEN NDHLOVU; Fiscal Year: 2015
  8. Richard E Chaisson; Fiscal Year: 2014
  9. JOAN WEINBERGER BERMAN; Fiscal Year: 2015
  10. HAART to Prevent HIV Transmission to Infants In Botswana
    Roger L Shapiro; Fiscal Year: 2010

Detail Information

Publications400 found, 100 shown here

  1. ncbi CD4+ count-guided interruption of antiretroviral treatment
    W M El-Sadr
    Division of Infectious Diseases, Harlem Hospital Center and Columbia University, New York, NY 10037, USA
    N Engl J Med 355:2283-96. 2006
    ..Despite declines in morbidity and mortality with the use of combination antiretroviral therapy, its effectiveness is limited by adverse events, problems with adherence, and resistance of the human immunodeficiency virus (HIV)...
  2. pmc Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis
    Deborah Donnell
    Statistical Center for HIV AIDS Research and Prevention and the Vaccine and Infectious Disease Institute, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Lancet 375:2092-8. 2010
    ..Initiation of antiretroviral therapy (ART) reduces plasma HIV-1 concentrations. We aimed to assess the effect of ART use by patients infected with HIV-1 on risk of transmission to their uninfected partners...
  3. pmc Early antiretroviral therapy and mortality among HIV-infected infants
    Avy Violari
    Perinatal HIV Research Unit, University of the Witwatersrand, Johannesburg, South Africa
    N Engl J Med 359:2233-44. 2008
    ..We investigated antiretroviral-treatment strategies in the Children with HIV Early Antiretroviral Therapy (CHER) trial...
  4. doi Effect of point-of-care CD4 cell count tests on retention of patients and rates of antiretroviral therapy initiation in primary health clinics: an observational cohort study
    Ilesh V Jani
    Instituto Nacional da Saúde, Maputo, Mozambique
    Lancet 378:1572-9. 2011
    ..We implemented point-of-care counting of CD4 cells in Mozambique and assessed the effect on loss to follow-up before immunological staging and treatment initiation...
  5. pmc Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis
    Francois Xavier Blanc
    Pneumology Unit, Internal Medicine Department, Bicetre Hospital, Assistance Publique Hopitaux de Paris, Le Kremlin Bicetre, France
    N Engl J Med 365:1471-81. 2011
    ..Robust data are lacking with regard to the timing for the initiation of antiretroviral therapy (ART) in relation to the start of antituberculosis therapy...
  6. pmc Timing of antiretroviral therapy for HIV-1 infection and tuberculosis
    Diane V Havlir
    University of California, San Francisco, 995 Potrero Ave, Bldg 80, Ward 84, San Francisco, CA 94110 2897, USA
    N Engl J Med 365:1482-91. 2011
    ....
  7. ncbi Decline in the AIDS and death rates in the EuroSIDA study: an observational study
    A Mocroft
    Royal Free Centre for HIV Medicine and Department of Primary Care and Population Sciences, Royal Free and University College Medical School, London, UK
    Lancet 362:22-9. 2003
    ..Since the introduction of highly active antiretroviral therapy (HAART), little is known about whether changes in HIV-1 mortality and morbidity rates have been sustained. We aimed to assess possible changes in these rates across Europe...
  8. doi Effect of earlier initiation of antiretroviral treatment and increased treatment coverage on HIV-related mortality in China: a national observational cohort study
    Fujie Zhang
    Division of Treatment and Care, National Centre for AIDS STD Control and Prevention, Chinese Centre for Disease Control and Prevention, Beijing, China
    Lancet Infect Dis 11:516-24. 2011
    ..Overall HIV mortality rates in China have not been reported. In this analysis we assess overall mortality in treatment-eligible adults with HIV and attempt to identify risk factors for HIV-related mortality...
  9. pmc Gender differences in survival among adult patients starting antiretroviral therapy in South Africa: a multicentre cohort study
    Morna Cornell
    Centre for Infectious Disease Epidemiology and Research, School of Public Health and Family Medicine, University of Cape Town, Cape Town, South Africa
    PLoS Med 9:e1001304. 2012
    ..Increased mortality among men on antiretroviral therapy (ART) has been documented but remains poorly understood. We examined the magnitude of and risk factors for gender differences in mortality on ART...
  10. pmc Second-line treatment in the Malawi antiretroviral programme: high early mortality, but good outcomes in survivors, despite extensive drug resistance at baseline
    M C Hosseinipour
    University of North Carolina Project, Lilongwe, Malawi
    HIV Med 11:510-8. 2010
    ..Advanced disease progression may occur before switching to second-line ART. We report outcomes for patients evaluated and initiated on second-line treatment in Malawi...
  11. ncbi Immune activation set point during early HIV infection predicts subsequent CD4+ T-cell changes independent of viral load
    Steven G Deeks
    San Francisco General Hospital, 995 Potrero Ave, San Francisco, CA 94110, USA
    Blood 104:942-7. 2004
    ..These data indicate that immunologic activation set point is established early in HIV infection, and that this set point determines the rate at which CD4+ T cells are lost over time...
  12. ncbi The WHO public-health approach to antiretroviral treatment against HIV in resource-limited settings
    Charles F Gilks
    Department of HIV AIDS, World Health Organization, Geneva 1211, Switzerland
    Lancet 368:505-10. 2006
    ..Simplified operational guidelines, tools, and training materials enable clinical teams in primary-care and second-level facilities to deliver HIV prevention, HIV care, and ART, and to use a standardised patient-tracking system...
  13. ncbi Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies
    Matthias Egger
    Department of Social and Preventive Medicine, University of Bern, CH 3012 Bern, Switzerland
    Lancet 360:119-29. 2002
    ..The ART Cohort Collaboration, which includes 13 cohort studies from Europe and North America, was established to fill this knowledge gap...
  14. pmc HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation
    Nicolas Chomont
    Laboratoire d Immunologie, Centre de Recherche du Centre Hospitalier de l Université de Montréal Saint Luc, Montreal, Quebec, Canada
    Nat Med 15:893-900. 2009
    ....
  15. pmc Temporal changes in programme outcomes among adult patients initiating antiretroviral therapy across South Africa, 2002-2007
    Morna Cornell
    Centre for Infectious Disease Epidemiology and Research, University of Cape Town, South Africa
    AIDS 24:2263-70. 2010
    ..We describe patient outcomes [mortality, loss-to-follow-up (LTFU) and retention] over time in a network of South African ART cohorts...
  16. doi Seven-year experience of a primary care antiretroviral treatment programme in Khayelitsha, South Africa
    Andrew Boulle
    School of Public Health and Family Medicine, University of Cape Town, Anzio Road, Cape Town, South Africa
    AIDS 24:563-72. 2010
    ..We report on outcomes after 7 years of a community-based antiretroviral therapy (ART) programme in Khayelitsha, South Africa, with death registry linkages to correct for mortality under-ascertainment...
  17. pmc Rates of virological failure in patients treated in a home-based versus a facility-based HIV-care model in Jinja, southeast Uganda: a cluster-randomised equivalence trial
    Shabbar Jaffar
    Department of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London, UK
    Lancet 374:2080-9. 2009
    ..Identification of new ways to increase access to antiretroviral therapy in Africa is an urgent priority. We assessed whether home-based HIV care was as effective as was facility-based care...
  18. pmc Maternal or infant antiretroviral drugs to reduce HIV-1 transmission
    Charles S Chasela
    University of North Carolina Project, Lilongwe, Malawi
    N Engl J Med 362:2271-81. 2010
    ..We evaluated the efficacy of a maternal triple-drug antiretroviral regimen or infant nevirapine prophylaxis for 28 weeks during breast-feeding to reduce postnatal transmission of human immunodeficiency virus type 1 (HIV-1) in Malawi...
  19. ncbi T cell activation is associated with lower CD4+ T cell gains in human immunodeficiency virus-infected patients with sustained viral suppression during antiretroviral therapy
    Peter W Hunt
    Positive Health Program, San Francisco General Hospital, and San Francisco Veterans Affairs Medical Center, San Francisco, California 94121, USA
    J Infect Dis 187:1534-43. 2003
    ..Interventions that directly target T cell activation or the determinants of activation may prove to be useful adjuvants to antiretroviral therapy...
  20. pmc CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells
    Weihong Liu
    UCSF Diabetes Center, Department of Medicine, University of California, San Francisco, San Francisco, CA 94143, USA
    J Exp Med 203:1701-11. 2006
    ..Finally, we show that CD127 can be used to quantitate T reg cell subsets in individuals with type 1 diabetes supporting the use of CD127 as a biomarker for human T reg cells...
  21. ncbi Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries
    Paula Braitstein
    Lancet 367:817-24. 2006
    ..We compared baseline characteristics and outcomes during the first year of HAART between HIV-1-infected patients in low-income and high-income settings...
  22. pmc Four-year treatment outcomes of adult patients enrolled in Mozambique's rapidly expanding antiretroviral therapy program
    Andrew F Auld
    Division of Global AIDS, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America
    PLoS ONE 6:e18453. 2011
    ..All ART patients were eligible for co-trimoxazole. ART program outcomes, and determinants of outcomes, have not yet been reported...
  23. doi Life expectancy of persons receiving combination antiretroviral therapy in low-income countries: a cohort analysis from Uganda
    Edward J Mills
    University of Ottawa, Ottawa, Ontario, Canada
    Ann Intern Med 155:209-16. 2011
    ..Little is known about the effect of combination antiretroviral therapy (cART) on life expectancy in sub-Saharan Africa...
  24. ncbi Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study
    Rainer Weber
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital, CH 809a Zurich, Switzerland
    Arch Intern Med 166:1632-41. 2006
    ..An increasing proportion of deaths among human immunodeficiency virus (HIV)-infected persons with access to combination antiretroviral therapy (cART) are due to complications of liver diseases...
  25. ncbi Combination antiretroviral strategies for the treatment of pregnant HIV-1-infected women and prevention of perinatal HIV-1 transmission
    Ellen R Cooper
    Maxwell Finland Laboratory for Infectious Diseases, Boston Medical Center, Boston University School of Medicine, 774 Albany Street, Suite 506, Boston, MA 02118, U S A
    J Acquir Immune Defic Syndr 29:484-94. 2002
    ..The Women and Infants Transmission Study is a prospective natural history study that has been enrolling HIV-1-infected pregnant women and their infants since 1989...
  26. ncbi Burden of tuberculosis in an antiretroviral treatment programme in sub-Saharan Africa: impact on treatment outcomes and implications for tuberculosis control
    Stephen D Lawn
    Desmond Tutu HIV Centre, Institute for Infectious Disease and Molecular Medicine, South Africa
    AIDS 20:1605-12. 2006
    ..To determine burden and risk factors for tuberculosis (TB) in an antiretroviral treatment (ART) programme and its impact on ART outcomes...
  27. pmc Rapid scaling-up of antiretroviral therapy in 10,000 adults in Côte d'Ivoire: 2-year outcomes and determinants
    Siaka Toure
    Aconda Association, Abidjan, Cote d Ivoire
    AIDS 22:873-82. 2008
    ..To assess the rates and determinants of mortality, loss to follow-up and immunological failure in a nongovernmental organization-implemented program of access to antiretroviral treatment in Côte d'Ivoire...
  28. doi Low rates of mother-to-child transmission of HIV following effective pregnancy interventions in the United Kingdom and Ireland, 2000-2006
    Claire L Townsend
    MRC Centre of Epidemiology for Child Health, UCL Institute of Child Health, University College London, London, UK
    AIDS 22:973-81. 2008
    ..The aim of this analysis was to explore the impact of different strategies to prevent mother-to-child transmission at a population level...
  29. pmc Long-term immunologic response to antiretroviral therapy in low-income countries: a collaborative analysis of prospective studies
    Denis Nash
    Columbia University, Mailman School of Public Health, International Center for AIDS Care and Treatment Programs and Department of Epidemiology, 722 W 168th Street, Room 706, New York, NY 10032 USA
    AIDS 22:2291-302. 2008
    ..Few data are available on the long-term immunologic response to antiretroviral therapy (ART) in resource-limited settings, where ART is being rapidly scaled up using a public health approach, with a limited repertoire of drugs...
  30. pmc Effect of early versus deferred antiretroviral therapy for HIV on survival
    Mari M Kitahata
    University of Washington, Harborview Medical Center, 325 Ninth Ave, Box 359931, Seattle, WA 98104, USA
    N Engl J Med 360:1815-26. 2009
    ..The optimal time for the initiation of antiretroviral therapy for asymptomatic patients with human immunodeficiency virus (HIV) infection is uncertain...
  31. pmc Changes in programmatic outcomes during 7 years of scale-up at a community-based antiretroviral treatment service in South Africa
    Mweete D Nglazi
    The Desmond Tutu HIV Centre, Institute for Infectious Disease and Molecular Medicine, Department of Medicine, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa
    J Acquir Immune Defic Syndr 56:e1-8. 2011
    ..To assess sustainability of programmatic outcomes in a community-based antiretroviral therapy (ART) service in South Africa during 7 years of scale-up...
  32. pmc Outcomes of antiretroviral treatment in programmes with and without routine viral load monitoring in Southern Africa
    Olivia Keiser
    Division of International and Environmental Health, Institute of Social and Preventive Medicine, University of Bern, Switzerland
    AIDS 25:1761-9. 2011
    ..To compare outcomes of antiretroviral therapy (ART) in South Africa, where viral load monitoring is routine, with those in Malawi and Zambia, where monitoring is based on CD4 cell counts...
  33. doi Projected life expectancy of people with HIV according to timing of diagnosis
    Fumiyo Nakagawa
    HIV Epidemiology and Biostatistics Group, Research Department of Infection and Population Health, University College London, UK
    AIDS 26:335-43. 2012
    ..Our aims were to estimate the life expectancy of an HIV-infected MSM living in a developed country with extensive access to ART and healthcare, and to assess the effect of late diagnosis on life expectancy...
  34. doi Time from human immunodeficiency virus seroconversion to reaching CD4+ cell count thresholds <200, <350, and <500 Cells/mm³: assessment of need following changes in treatment guidelines
    Sara Lodi
    MRC Clinical Trials Unit, University College London, UK
    Clin Infect Dis 53:817-25. 2011
    ....
  35. pmc Mortality and loss-to-follow-up during the pre-treatment period in an antiretroviral therapy programme under normal health service conditions in Uganda
    Barbara Amuron
    MRC UVRI Uganda Research Unit on AIDS, Uganda
    BMC Public Health 9:290. 2009
    ..The rates of mortality and retention during the pre-treatment period are not well understood. We conducted an observational study to determine these rates...
  36. pmc The impact of the new WHO antiretroviral treatment guidelines on HIV epidemic dynamics and cost in South Africa
    Jan A C Hontelez
    Department of Public Health, Erasmus MC, University Medical Centre Rotterdam, Rotterdam, The Netherlands
    PLoS ONE 6:e21919. 2011
    ..South Africa decided to adopt this strategy for pregnant and TB co-infected patients only. We estimated the impact of fully adopting the new WHO guidelines on HIV epidemic dynamics and associated costs...
  37. pmc Immunologic criteria are poor predictors of virologic outcome: implications for HIV treatment monitoring in resource-limited settings
    Holly E Rawizza
    Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
    Clin Infect Dis 53:1283-90. 2011
    ..In the absence of VL monitoring, switches to second-line ART are based on World Health Organization (WHO) clinical or immunologic failure criteria...
  38. pmc Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised non-inferiority trial
    P Mugyenyi
    MRC Clinical Trials Unit, 222 Euston Road, London NW1 2DA, UK
    Lancet 375:123-31. 2010
    ..This trial investigated whether routine toxicity and efficacy monitoring of HIV-infected patients receiving ART had an important long-term effect on clinical outcomes in Africa...
  39. ncbi Cost-effectiveness of HIV treatment in resource-poor settings--the case of Côte d'Ivoire
    Sue J Goldie
    Department of Health Policy and Management, Program in Health Decision Science, Harvard School of Public Health, Boston, MA 02115, USA
    N Engl J Med 355:1141-53. 2006
    ..As antiretroviral therapy is increasingly used in settings with limited resources, key questions about the timing of treatment and use of diagnostic tests to guide clinical decisions must be addressed...
  40. pmc Enhanced T cell recovery in HIV-1-infected adults through IL-7 treatment
    Yves Levy
    1INSERM U955, Universite Paris 12, and Assistance Publique Hôpitaux de Paris AP HP, Groupe Henri Mondor Albert Chenevier, Immunologie Clinique, Creteil, France
    J Clin Invest 119:997-1007. 2009
    ..Therefore, patients may benefit from intermittent therapy with IL-7 in combination with c-ART...
  41. ncbi Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease
    B Autran
    Laboratoire d Immunologie Cellulaire, URA CNRS 625, Hopital Pitie Salpetriere, 47 83 boulevard de l Hopital, Paris, France
    Science 277:112-6. 1997
    ..Thus, decreasing the HIV load can reverse HIV-driven activation and CD4(+) T cell defects in advanced HIV-infected patients...
  42. pmc Antiretroviral therapy adherence, virologic and immunologic outcomes in adolescents compared with adults in southern Africa
    Jean B Nachega
    Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
    J Acquir Immune Defic Syndr 51:65-71. 2009
    ..To determine adherence to and effectiveness of antiretroviral therapy (ART) in adolescents vs. adults in southern Africa...
  43. doi Effect on transmission of HIV-1 resistance of timing of implementation of viral load monitoring to determine switches from first to second-line antiretroviral regimens in resource-limited settings
    Andrew N Phillips
    Department of Infection and Population Health, UCL, UK
    AIDS 25:843-50. 2011
    ..There is concern that antiretroviral therapy (ART) use with only clinical monitoring for failure will result in high rates of transmission of virus with resistance to drugs currently in use...
  44. doi Monitoring of HIV viral loads, CD4 cell counts, and clinical assessments versus clinical monitoring alone for antiretroviral therapy in rural district hospitals in Cameroon (Stratall ANRS 12110/ESTHER): a randomised non-inferiority trial
    Christian Laurent
    Institut de recherche pour le developpement IRD, University Montpellier 1, UMI 233, Montpellier, France
    Lancet Infect Dis 11:825-33. 2011
    ..We aimed to assess the effectiveness and safety of clinical monitoring alone (CLIN) in terms of non-inferiority to laboratory and clinical monitoring (LAB)...
  45. pmc Low retention of HIV-infected patients on antiretroviral therapy in 11 clinical centres in West Africa
    Didier K Ekouevi
    INSERM, U897, and ISPED, Universite Bordeaux 2, Bordeaux, France
    Trop Med Int Health 15:34-42. 2010
    ..To study factors associated with the probability of retention in antiretroviral therapy (ART) programmes in West Africa...
  46. pmc Administration of rhIL-7 in humans increases in vivo TCR repertoire diversity by preferential expansion of naive T cell subsets
    Claude Sportes
    Experimental Transplantation and Immunology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA
    J Exp Med 205:1701-14. 2008
    ....
  47. pmc Retention in care among HIV-infected patients in resource-limited settings: emerging insights and new directions
    Elvin H Geng
    Division of HIV AIDS at San Francisco General Hospital, 995 Potrero Avenue, San Francisco, CA 94110, USA
    Curr HIV/AIDS Rep 7:234-44. 2010
    ..Research to assess and improve retention in care for HIV-infected patients can be strengthened by incorporating novel methods such as sampling-based approaches and a causal analytic framework...
  48. doi Age and CD4 count at initiation of antiretroviral therapy in HIV-infected children: effects on long-term T-cell reconstitution
    Joanna Lewis
    Immunobiology Unit, Institute of Child Health, UK
    J Infect Dis 205:548-56. 2012
    ..We describe the effects of children's age and pre-antiretroviral therapy (ART) CD4 count on long-term CD4 T-cell reconstitution...
  49. pmc Program-level and contextual-level determinants of low-median CD4+ cell count in cohorts of persons initiating ART in eight sub-Saharan African countries
    Denis Nash
    International Center for AIDS Care and Treatment Programs, Columbia University Mailman School of Public Health, New York, New York, USA
    AIDS 25:1523-33. 2011
    ..We examined program-level and contextual-level factors associated with low median CD4 cell count at ART initiation in populations initiating ART...
  50. pmc CD4 cell count and viral load monitoring in patients undergoing antiretroviral therapy in Uganda: cost effectiveness study
    James G Kahn
    Philip R Lee Institute for Health Policy Studies and Department of Epidemiology and Biostatistics, University of California, San Francisco, CA, USA
    BMJ 343:d6884. 2011
    ..To examine the cost and cost effectiveness of quarterly CD4 cell count and viral load monitoring among patients taking antiretroviral therapy (ART)...
  51. ncbi Persistent immune activation in HIV-1 infection is associated with progression to AIDS
    Mette D Hazenberg
    Department of Clinical Viro Immunology, Sanquin Research at CLB, Tropical Medicine and AIDS, Amsterdam, The Netherlands
    AIDS 17:1881-8. 2003
    ..HIV-1 infection is characterized by chronic generalized CD8 and CD4 T cell hyperactivation, the biological effect of which is not understood...
  52. ncbi Natural history and possible reactivation of human papillomavirus in human immunodeficiency virus-positive women
    Howard D Strickler
    Department of Epidemiology and Population Health, Albert Einstein College of Medicine, 1300 Morris Park Ave, Belfer 1308, Bronx, NY 10461, USA
    J Natl Cancer Inst 97:577-86. 2005
    ....
  53. pmc The impact of gender and income on survival and retention in a South African antiretroviral therapy programme
    Morna Cornell
    University of Cape Town, South Africa
    Trop Med Int Health 14:722-31. 2009
    ..We investigated the association of gender and income with survival and retention in a South African ART programme...
  54. doi Evaluation of the PIMA point-of-care CD4 analyzer in VCT clinics in Zimbabwe
    Sekesai Mtapuri-Zinyowera
    National Microbiology Reference Laboratory, Harare, Zimbabwe
    J Acquir Immune Defic Syndr 55:1-7. 2010
    ..POC CD4 may also alleviate testing burdens at traditional central CD4 laboratories, hence improving test access in both rural and urban environments...
  55. ncbi Effect of HIV-1 and increasing immunosuppression on malaria parasitaemia and clinical episodes in adults in rural Uganda: a cohort study
    J Whitworth
    Medical Research Council Programme on AIDS, Uganda Virus Research Institute, Entebbe
    Lancet 356:1051-6. 2000
    ..An association between HIV-1 and malaria is expected in theory, but has not been convincingly shown in practice. We studied the effects of HIV-1 infection and advancing immunosuppression on falciparum parasitaemia and clinical malaria...
  56. pmc Outcomes after virologic failure of first-line ART in South Africa
    Richard A Murphy
    Operational Support Unit, Doctors Without Borders, New York, New York 10001, USA
    AIDS 24:1007-12. 2010
    ..To determine initial 24-week outcomes among prospectively enrolled patients with failure of initial antiretroviral therapy (ART)...
  57. pmc Late presentation for human immunodeficiency virus care in the United States and Canada
    Keri N Althoff
    Johns Hopkins University, Baltimore, Maryland, USA
    Clin Infect Dis 50:1512-20. 2010
    ..CONCLUSION. CD4 count at first presentation for HIV care has increased annually over the past 11 years but has remained <350 cells/mm(3), which suggests the urgent need for earlier HIV diagnosis and treatment...
  58. doi Vital status of pre-ART and ART patients defaulting from care in rural Malawi
    Megan McGuire
    Medecins Sans Frontieres, Chiradzulu, Malawi
    Trop Med Int Health 15:55-62. 2010
    ..To ascertain the outcome of pre-Antiretroviral therapy (ART) and ART patients defaulting from care and investigate reasons for defaulting...
  59. pmc Screening for cryptococcal antigenemia in patients accessing an antiretroviral treatment program in South Africa
    Joseph N Jarvis
    Department of Medicine, Division of Infectious Diseases, Desmond Tutu HIV Centre, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa
    Clin Infect Dis 48:856-62. 2009
    ..Screening for cryptococcal antigen in patients who enroll in ART programs may identify those at risk of cryptococcal meningitis and permit targeted use of preemptive therapy...
  60. pmc The public health approach to identify antiretroviral therapy failure: high-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy
    Mina C Hosseinipour
    University of North Carolina Project, Lilongwe, Malawi
    AIDS 23:1127-34. 2009
    ..We evaluated drug resistance patterns among patients failing first-line ART on the basis of clinical or immunological criteria in Lilongwe and Blantyre, Malawi...
  61. doi Factors associated with specific causes of death amongst HIV-positive individuals in the D:A:D Study
    Colette Smith
    Research Department of Infection and Population Health, UCL, Royal Free Campus, London, UK
    AIDS 24:1537-48. 2010
    ..To investigate any emerging trends in causes of death amongst HIV-positive individuals in the current cART era, and to investigate the factors associated with each specific cause of death...
  62. pmc Cost-effectiveness of serum cryptococcal antigen screening to prevent deaths among HIV-infected persons with a CD4+ cell count < or = 100 cells/microL who start HIV therapy in resource-limited settings
    David B Meya
    Infectious Disease Institute, Makerere University, Mulago Hospital Complex, Kampala, Uganda
    Clin Infect Dis 51:448-55. 2010
    ..We sought to define the cost-effectiveness of serum cryptococcal antigen (CRAG) screening to identify persons with subclinical cryptococcosis and the efficacy of preemptive fluconazole therapy...
  63. ncbi Rapid scale-up of antiretroviral therapy at primary care sites in Zambia: feasibility and early outcomes
    Jeffrey S A Stringer
    Schools of Medicine and Public Health, University of Alabama at Birmingham, Birmingham, USA
    JAMA 296:782-93. 2006
    ..The Zambian Ministry of Health has scaled-up human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS) care and treatment services at primary care clinics in Lusaka, using predominately nonphysician clinicians...
  64. doi Microbial translocation is associated with sustained failure in CD4+ T-cell reconstitution in HIV-infected patients on long-term highly active antiretroviral therapy
    Giulia Marchetti
    Department of Medicine, Surgery and Dentistry, Clinic of Infectious Diseases, San Paolo Hospital, University of Milan, Milan, Italy
    AIDS 22:2035-8. 2008
    ..These data provide novel insight into INRs pathogenesis, since they correlate augmented systemic translocation of microbial bioproducts with T-cell hyperactivation...
  65. pmc Isoniazid preventive therapy, HAART and tuberculosis risk in HIV-infected adults in South Africa: a prospective cohort
    Jonathan E Golub
    Johns Hopkins University, School of Medicine, 1550 Orleans St, 1M 07 Baltimore, MD 21231, USA
    AIDS 23:631-6. 2009
    ..There is less information on the combined effect of IPT and HAART. We assessed the effect of IPT, HAART or both IPT and HAART on tuberculosis incidence in HIV-infected adults in South Africa...
  66. pmc Relationship between T cell activation and CD4+ T cell count in HIV-seropositive individuals with undetectable plasma HIV RNA levels in the absence of therapy
    Peter W Hunt
    Positive Health Program, San Francisco General Hospital, Bldg 80, Ward 84, 995 Potrero Ave, San Francisco, CA 94110, USA
    J Infect Dis 197:126-33. 2008
    ....
  67. pmc Loss to follow-up of adults in public HIV care systems in central Mozambique: identifying obstacles to treatment
    Mark A Micek
    Department of Global Health, University of Washington, Seattle, WA 09195, USA
    J Acquir Immune Defic Syndr 52:397-405. 2009
    ..Access to antiretroviral treatment (ART) has expanded dramatically in resource-limited settings. Evaluating loss to follow-up from HIV testing through post-ART care can help identify obstacles to care...
  68. doi Initiation of highly active antiretroviral therapy among pregnant women in Cape Town, South Africa
    Kathryn Stinson
    Centre for Infectious Disease Epidemiology and Research, School of Public Health and Family Medicine, University of Cape Town, Cape Town, South Africa
    Trop Med Int Health 15:825-32. 2010
    ..To investigate highly active antiretroviral therapy (HAART) initiation among pregnant women and the optimum model of service delivery for integrating HAART services into antenatal care...
  69. doi Sex differences in antiretroviral treatment outcomes among HIV-infected adults in an urban Tanzanian setting
    Claudia Hawkins
    Division of Infectious Diseases, Northwestern University, Chicago, Illinois 60611, USA
    AIDS 25:1189-97. 2011
    ..To determine the relationship between sex and antiretroviral therapy (ART) outcomes in an urban Tanzanian setting...
  70. pmc Implementation of free cotrimoxazole prophylaxis improves clinic retention among antiretroviral therapy-ineligible clients in Kenya
    Pamela K Kohler
    Department of Global Health, University of Washington, Seattle, 98104, USA
    AIDS 25:1657-61. 2011
    ..To determine whether implementation of free cotrimoxazole (CTX) provision was associated with improved retention among clients ineligible for antiretroviral therapy (ART) enrolled in an HIV treatment program in Kenya...
  71. pmc Antiretroviral therapy responses among children attending a large public clinic in Soweto, South Africa
    Tammy M Meyers
    Department of Paediatrics, Harriet Shezi Children s Clinic, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
    Pediatr Infect Dis J 30:974-9. 2011
    ..The aim of this study was to determine treatment responses of children in a routine setting where first-line therapy with lopinavir/ritonavir is routinely included for young children...
  72. pmc Utility of routine viral load, CD4 cell count, and clinical monitoring among adults with HIV receiving antiretroviral therapy in Uganda: randomised trial
    Jonathan Mermin
    Global AIDS Program, Centers for Disease Control and Prevention Uganda, Entebbe, Uganda
    BMJ 343:d6792. 2011
    ..To evaluate the use of routine laboratory monitoring in terms of clinical outcomes among patients receiving antiretroviral therapy (ART) in Uganda...
  73. pmc Performance evaluation of the Pima™ point-of-care CD4 analyser using capillary blood sampling in field tests in South Africa
    Deborah K Glencross
    Department of Molecular Medicine and Haematology, Faculty of Health Sciences, University of the Witwatersrand, 7 York Road, Parktown, 2198, Johannesburg, South Africa
    J Int AIDS Soc 15:3. 2012
    ..This study evaluated performance of capillary blood sampling using the point-of-care Pima™ CD4 device in representative primary health care clinics doing HIV testing...
  74. pmc Tuberculosis incidence rates during 8 years of follow-up of an antiretroviral treatment cohort in South Africa: comparison with rates in the community
    Ankur Gupta
    Department of Clinical Research, Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, United Kingdom
    PLoS ONE 7:e34156. 2012
    ..We compared these rates with those of HIV-uninfected individuals living in the same community...
  75. pmc Early antiretroviral therapy improves neurodevelopmental outcomes in infants
    Barbara Laughton
    Children s Infectious Diseases Clinical Research Unit, Department of Paediatrics and Child Health, Stellenbosch University and Tygerberg Children s Hospital, Cape Town, South Africa
    AIDS 26:1685-90. 2012
    ..To evaluate the effect of early versus deferred antiretroviral therapy (ART) on the neurodevelopment of infants from Cape Town participating in the Children with HIV Early Antiretroviral Therapy (CHER) trial...
  76. pmc Outcomes of antiretroviral therapy in children in Asia and Africa: a comparative analysis of the IeDEA pediatric multiregional collaboration
    Valeriane Leroy
    INSERM, U897, Epidemiologie Biostatistiques Bordeaux, France
    J Acquir Immune Defic Syndr 62:208-19. 2013
    ..We investigated 18-month incidence and determinants of death and loss to follow-up of children after antiretroviral therapy (ART) initiation in a multiregional collaboration in lower-income countries...
  77. pmc Decreased sexual risk behavior in the era of HAART among HIV-infected urban and rural South Africans attending primary care clinics
    Kartik K Venkatesh
    Department of Community Health, Brown University, Providence, Rhode Island, USA
    AIDS 24:2687-96. 2010
    ..In light of increasing access to HAART in sub-Saharan Africa, we conducted a longitudinal study to assess the impact of HAART on sexual risk behaviors among HIV-infected South Africans in urban and rural primary care clinics...
  78. pmc Retention in HIV care for individuals not yet eligible for antiretroviral therapy: rural KwaZulu-Natal, South Africa
    Richard J Lessells
    Africa Centre for Health and Population Studies, University of KwaZulu Natal, Mtubatuba, South Africa
    J Acquir Immune Defic Syndr 56:e79-86. 2011
    ..To determine retention in HIV care for individuals not yet eligible for antiretroviral therapy (ART) and to explore factors associated with retention in a rural public health HIV program...
  79. pmc Switching to second-line antiretroviral therapy in resource-limited settings: comparison of programmes with and without viral load monitoring
    Olivia Keiser
    Institute of Social and Preventive Medicine ISPM, University of Bern, Bern, Switzerland
    AIDS 23:1867-74. 2009
    ..We examined switching from nonnucleoside reverse transcriptase inhibitor (NNRTI)-based first-line regimens to protease inhibitor-based regimens in Africa, South America and Asia...
  80. pmc Who starts antiretroviral therapy in Durban, South Africa?... not everyone who should
    Ingrid V Bassett
    Division of Infectious Disease, Massachusetts General Hospital, Boston, MA 02114, USA
    AIDS 24:S37-44. 2010
    ..To evaluate rates of antiretroviral therapy (ART) initiation within 12 months of a new HIV diagnosis in Durban, South Africa...
  81. pmc Timing of initiation of antiretroviral drugs during tuberculosis therapy
    Salim S Abdool Karim
    Centre for the AIDS Programme of Research in South Africa, University of KwaZulu Natal, Durban, South Africa
    N Engl J Med 362:697-706. 2010
    ..The optimal timing for the initiation of antiretroviral therapy in relation to tuberculosis therapy remains controversial...
  82. pmc Antiretroviral therapies in women after single-dose nevirapine exposure
    Shahin Lockman
    Brigham and Women s Hospital, Boston, MA, USA
    N Engl J Med 363:1499-509. 2010
    ..Peripartum administration of single-dose nevirapine reduces mother-to-child transmission of human immunodeficiency virus type 1 (HIV-1) but selects for nevirapine-resistant virus...
  83. doi Hydroxychloroquine drastically reduces immune activation in HIV-infected, antiretroviral therapy-treated immunologic nonresponders
    Stefania Piconi
    I Divisione Malattie Infettive, H L Sacco, Milan, Italy
    Blood 118:3263-72. 2011
    ..HCQ reduces lipopolysaccharide/TLR-mediated immune activation; this compound could be a useful immunomodulant in HIV-infected patients. This study is registered at EutraCT as 2009-012499-28 with study number HLS01/2009-1-16-03-2009...
  84. doi Providing immediate CD4 count results at HIV testing improves ART initiation
    Mamsallah Faal
    WITS Reproductive Health and HIV Institute, University of the Witwatersrand, Johannesburg, South Africa
    J Acquir Immune Defic Syndr 58:e54-9. 2011
    ..We evaluated the impact of a CD4 count result and patient written information provided immediately after diagnosis on retention in care...
  85. pmc When to start antiretroviral therapy in resource-limited settings
    Rochelle P Walensky
    Massachusetts General Hospital, Brigham and Women s Hospital, Harvard University Medical School, Harvard School of Public Health, and Boston University School of Public Health, Boston, Massachusetts 02114, USA
    Ann Intern Med 151:157-66. 2009
    ..The results of international clinical trials that are assessing when to initiate antiretroviral therapy (ART) will not be available for several years...
  86. ncbi Mortality, CD4 cell count decline, and depressive symptoms among HIV-seropositive women: longitudinal analysis from the HIV Epidemiology Research Study
    J R Ickovics
    Yale University, Department of Epidemiology and Public Health, PO Box 208034, 60 College St, Suite 415, New Haven, CT 06520 8034, USA
    JAMA 285:1466-74. 2001
    ..The impact of depression on morbidity and mortality among women with human immunodeficiency virus (HIV) has not been examined despite the fact that women with HIV have substantially higher rates of depression than their male counterparts...
  87. pmc Aging and infectious diseases: do patterns of comorbidity vary by HIV status, age, and HIV severity?
    Joseph L Goulet
    Veterans Affairs Connecticut Healthcare System, West Haven, CT 06516, USA
    Clin Infect Dis 45:1593-601. 2007
    ..Patterns of comorbidity differ substantially by HIV status, age, and HIV severity. Primary care guidelines require adaptation for persons with HIV infection...
  88. pmc Early loss of HIV-infected patients on potent antiretroviral therapy programmes in lower-income countries
    Martin W G Brinkhof
    Institute of Social and Preventive Medicine, Bern, Switzerland
    Bull World Health Organ 86:559-67. 2008
    ..To analyse the early loss of patients to antiretroviral therapy (ART) programmes in resource-limited settings...
  89. pmc Role of viral replication, antiretroviral therapy, and immunodeficiency in HIV-associated atherosclerosis
    Priscilla Y Hsue
    Division of Cardiology, San Francisco General Hospital, San Francisco, California 94110, USA
    AIDS 23:1059-67. 2009
    ....
  90. pmc Human immunodeficiency virus (HIV) type 1 proviral hypermutation correlates with CD4 count in HIV-infected women from Kenya
    Allison M Land
    Department of Medical Microbiology, University of Manitoba, Winnipeg, Manitoba R3E 0W3, Canada
    J Virol 82:8172-82. 2008
    ..These findings support the potential of targeting APOBEC3F/G for therapeutic purposes...
  91. ncbi Tuberculosis-associated immune reconstitution disease: incidence, risk factors and impact in an antiretroviral treatment service in South Africa
    Stephen D Lawn
    Desmond Tutu HIV Centre, Institute for Infectious Disease and Molecular Medicine, Faculty of Health Sciences, University of Cape Town, Anzio Road, Observatory 7925, Cape Town, South Africa
    AIDS 21:335-41. 2007
    ..To determine the burden and impact of immune reconstitution disease (IRD) associated with tuberculosis (TB) among patients initiating antiretroviral treatment (ART) in sub-Saharan Africa...
  92. ncbi Predictors of long-term viral failure among ugandan children and adults treated with antiretroviral therapy
    Moses R Kamya
    Department of Medicine, Makerere University, Kampala, Uganda
    J Acquir Immune Defic Syndr 46:187-93. 2007
    ..We identified predictors of viral failure and documented genotypic mutations in a subset of patients with viral failure after 12 months on antiretroviral therapy (ART)...
  93. pmc Incomplete peripheral CD4+ cell count restoration in HIV-infected patients receiving long-term antiretroviral treatment
    Colleen F Kelley
    Emory University, Atlanta, Georgia, USA
    Clin Infect Dis 48:787-94. 2009
    ....
  94. ncbi Long-term outcomes among antiretroviral-naive human immunodeficiency virus-infected patients with small increases in CD4+ cell counts after successful virologic suppression
    Fernando Dronda
    Servicio de Enfermedades Infecciosas, Hospital Ramon y Cajal, Madrid, Spain
    Clin Infect Dis 35:1005-9. 2002
    ..PI-containing regimens provided better immunologic response...
  95. ncbi CD4+ cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression
    Richard D Moore
    Johns Hopkins University School of Medicine, Baltimore, MD, USA
    Clin Infect Dis 44:441-6. 2007
    ..We characterized the increase in the CD4(+) cell count in patients in clinical practice who maintained sustained viral suppression for up to 6 years...
  96. pmc Misclassification of first-line antiretroviral treatment failure based on immunological monitoring of HIV infection in resource-limited settings
    Rami Kantor
    Division of Infectious Diseases, Brown University, Providence, Rhode Island, USA
    Clin Infect Dis 49:454-62. 2009
    ..The early identification of first-line antiretroviral treatment failure is critical to prevent morbidity, mortality, and drug resistance. Misclassification of failure may result in premature switching to second-line therapy...
  97. doi Effect of immunodeficiency, HIV viral load, and antiretroviral therapy on the risk of individual malignancies (FHDH-ANRS CO4): a prospective cohort study
    Marguerite Guiguet
    INSERM U943 and UPMC UMR S 943, Paris, France
    Lancet Oncol 10:1152-9. 2009
    ..We examined the effect of these factors on the risk of specific cancers in patients infected with HIV-1...
  98. ncbi Treatment of tuberculosis in HIV-infected persons in the era of highly active antiretroviral therapy
    Gillian L Dean
    St Thomas Hospital, London, UK
    AIDS 16:75-83. 2002
    ..To assess the risks and benefits of administering highly active antiretroviral therapy (HAART) during the treatment of tuberculosis (TB) in HIV-infected patients...
  99. ncbi Characteristics, determinants, and clinical relevance of CD4 T cell recovery to <500 cells/microL in HIV type 1-infected individuals receiving potent antiretroviral therapy
    Gilbert R Kaufmann
    Division of Infectious Diseases and Hospital Epidemiology, Department of Internal Medicine, University Hospital Basel, Basel, Switzerland
    Clin Infect Dis 41:361-72. 2005
    ..We studied the determinants and the clinical relevance of incomplete CD4 T cell restoration...
  100. ncbi CD4 cell counts of 800 cells/mm3 or greater after 7 years of highly active antiretroviral therapy are feasible in most patients starting with 350 cells/mm3 or greater
    Luuk Gras
    HIV Monitoring Foundation, Amsterdam, The Netherlands
    J Acquir Immune Defic Syndr 45:183-92. 2007
    ..CD4 cell count changes in therapy-naive patients were investigated during 7 years of highly active antiretroviral therapy (HAART) in an observational cohort...
  101. ncbi Late presenters in the era of highly active antiretroviral therapy: uptake of and responses to antiretroviral therapy
    Caroline A Sabin
    Royal Free and University College Medical School, Royal Free NHS Trust, London, UK
    AIDS 18:2145-51. 2004
    ..To investigate the characteristics and clinical, immunological and virological outcomes for individuals presenting for care with low CD4 cell counts...

Research Grants72

  1. EVA MARIA CARMONA PORQUERA; Fiscal Year: 2016
    ....
  2. Small Animal Model of HIV Neuropathogenesis in the HAART Era
    Pietro P Sanna; Fiscal Year: 2012
    ..Ultimately, the proposed Tg mice will allow mechanistic studies aimed at the generation of new pathogenetic hypotheses of HIV-associated neurocognitive disorders in the setting of HAART and their interaction with drugs of abuse. ..
  3. Longitudinal Studies of HIV-Associated Bacterial Pneumonia
    William N Rom; Fiscal Year: 2013
    ..We will freeze and store at -70 degrees plasma, serum, PBMC (RNA, DNA, protein), BAL, from involved/uninvolved lung segments, and sputum for collaborative studies with other NHLBI grantees. ..
  4. Suppressors of cytokine signaling (SOCS) in HAART-treated HIV infection
    Maria C Villacres; Fiscal Year: 2010
    ..As the number of HIV-infected women increase, especially among African-American and Latino minorities, it is highly relevant to understand the reasons for disease progression despite efficient anti-viral treatment. ..
  5. Alteration of circadian rhythm and sleep by HIV protein Tat
    Jian M Ding; Fiscal Year: 2012
    ..EEG analysis showed decreased delta power in the Tat transgenic mice compared to wild type mice. ..
  6. Non-CD4 Host defense against P. carinii Pneumonia
    Jay K Kolls; Fiscal Year: 2013
    ..3. Test the hypothesis that the combination of anti-Kex1 and anti-carbohydrate antibodies can mediate primary prophylaxis or treatment of PCP in T-cell deficient mice. ..
  7. CHIRATIDZO ELLEN NDHLOVU; Fiscal Year: 2015
    ..The successful implementation of this screening program through the use of low cost interventions has the potential to decrease incident cryptococcosis in ART treatment programs in sub-Saharan Africa. ..
  8. Richard E Chaisson; Fiscal Year: 2014
    ....
  9. JOAN WEINBERGER BERMAN; Fiscal Year: 2015
    ..We will also examine the mechanisms of PrPc release and the consequences of the soluble isoform on neuronal survival, astrocyte function and BBB integrity. ..
  10. HAART to Prevent HIV Transmission to Infants In Botswana
    Roger L Shapiro; Fiscal Year: 2010
    ..The Botswana government has given explicit support for this protocol to occur in four existing Botswana-Harvard AIDS Institute Partnership (BHP) locations to help guide future policy decisions. ..
  11. Multi-vitamins, HAART and HIV/AIDS in Uganda
    Wafaie W Fawzi; Fiscal Year: 2012
    ..In particular, multivitamins might confer important clinical benefits that would help preserve limited drug regimens in developing countries amidst increasing viral resistant HIV strains. ..
  12. Oral Transmission of HIV through Breastfeeding
    Louise Kuhn; Fiscal Year: 2013
    ..These studies will allow an in vivo evaluation of the potential role of anti-HIV innate mucosal immunity that will be informative for potential HIV vaccines that harness mucosal innate immunity. ..
  13. Marcia McDonnell Holstad; Fiscal Year: 2015
    ..3) Explore: a) the effects of LN on symptoms and symptom management;b) the roles of self-efficacy, outcome expectancies, and personal goal setting as mediators, and depression and health literacy as moderators of adherence. ..
  14. Jeffrey H Samet; Fiscal Year: 2016
    ..Importantly, if our hypotheses are true, zinc supplementation could ultimately become a standard adjunctive therapy complementing alcohol interventions among HIV+ persons even in resource limited environments. ..
  15. Immune Response to pneumococcal vaccination in HIV infected adults
    M A Westerink; Fiscal Year: 2009
    ..abstract_text> ..
  16. Nutrition and HIV Progression
    Christine A Wanke; Fiscal Year: 2013
    ..We propose to collect data on 200 women who are documented to be HIV-negative from Voi Division at a single visit, the Division that will also provide the HIV -infected women for the intervention study. ..
  17. LIPOGENESIS & LIPOPROTEIN COMPLICATIONS OF HIV THERAPY
    David Y Hui; Fiscal Year: 2010
    ..Aim 3 will compare the functionality of the HDL after HAART therapy to determine if these are pro- or anti-atherogenic. ..
  18. Evaluation of antiretroviral HIV prevention in African HIV discordant couples
    Jared Baeten; Fiscal Year: 2012
    ..We propose to evaluate user preferences and risk-based targeting of ART-based HIV-1 prevention among HIV-1 serodiscordant couples in Thika, Kenya. ..
  19. Serologic memory and prevention of Pneumocystis-related COPD in AIDS macaque mode
    Karen A Norris; Fiscal Year: 2011
    ..abstract_text> ..
  20. Jay K Kolls; Fiscal Year: 2016
    ..This research will improve the potential development of a vaccine for this infection. ..
  21. Immune Response to pneumococcal vaccination in HIV infected adults
    M A JULIA WESTERINK; Fiscal Year: 2013
    ..More importantly, the results of these studies could clarify controversies in the present vaccine recommendations in the HIV-infected population. ..
  22. Jeffrey T Parsons; Fiscal Year: 2016
    ....
  23. Low Cost Laser Diagnostic for CD4+ T Cell Counting
    Michael J Lochhead; Fiscal Year: 2013
    ..e., productin instruments, clinical trials, regulatory submission, and marketing will be accelerated. ..
  24. Allison Ross Eckard; Fiscal Year: 2016
    ..Future training in all aspects of clinical research, cardiovascular disease risk assessment, and clinical nutrition is planned to facilitate the PI's development into a successful independent physician scientist. ..
  25. Analyzing Patient-Provider Communication to Understand Disparities in HIV Care
    Ira B Wilson; Fiscal Year: 2010
    ..A unique feature of this new coding method is that it permits detailed assessment of antiretroviral medication adherence. ..
  26. JOCELYN CHRISTINE ANDERSON; Fiscal Year: 2015
    ..The findings from the proposed study will be used to inform culturally competent interventions to reduce health disparities among urban, HIV positive women. ..
  27. Understanding discontinuation of outpatient care among HIV-positive inpatients
    Lisa R Metsch; Fiscal Year: 2013
    ..g., poverty, housing instability) shape their health practices and health lifestyles. ..
  28. CD8+ T cell mediated inhibition of HIV-1 replication in Elite Suppressors
    Joel N Blankson; Fiscal Year: 2012
    ..This project plans to determine how CD8+ T cells from ES control the virus;the results may be applicable to the development of an effective HIV-1 vaccine. ..
  29. Clinical Relevance of GB Virus C & Hepatitis C Virus in HIV+ Women
    Jason T Blackard; Fiscal Year: 2010
    ..Such studies could ultimately lead to novel therapeutic strategies to treat HIV disease, particularly among difficult-to-treat populations and/or individuals with limited access to antiretroviral therapy. ..
  30. Effects of HIV and ARV Exposure on Child Health and Neurodevelopment in Botswana.
    Shahin Lockman; Fiscal Year: 2013
    ..We hope to evaluate both of these questions in Botswana in order to improve neurodevelopmental and health outcomes among children born to HIV-infected mothers globally. ..
  31. MICRONUTRIENTS AND ENTERIC INFECTION IN AFRICAN CHILDREN
    Sherwood Gorbach; Fiscal Year: 2005
    ..This study will also allow us to determine risk factors for persistent diarrhea, and to develop algorithms for the management of infectious diarrhea in a region where HIV infection is common. ..
  32. MICRONUTRIENTS AND ENTERIC INFECTION IN AFRICAN CHILDREN
    MICHAEL BENNISH; Fiscal Year: 2002
    ..This study will also allow us to determine risk factors for persistent diarrhea, and to develop algorithms for the management of infectious diarrhea in a region where HIV infection is common. ..
  33. Mwangelwa Mubiana-Mbewe; Fiscal Year: 2015
    ..To our knowledge, this operations research study will be the + first to look at the impact of POC CD4 testing on clinical outcomes. 2 ..
  34. A Flow Through Cell Counting Assay
    SIMON BYSTRYAK; Fiscal Year: 2010
    ..Successful completion of these studies will be beneficial for public health, and make available all of the technology needed for a substantial business opportunity to license the technology and manufacture commercial products. ..
  35. Diane V Havlir; Fiscal Year: 2016
    ..Outcomes of interest will include cost per: confirmation of meeting ART criteria;ART initiation;virologic suppression;averted death;averted vertical infection;and averted Disability-Adjusted Life Year (DALY). ..
  36. JUDITH JACQUELINE LOK; Fiscal Year: 2015
    ....
  37. GWAS on Determinants of HIV-1 Subtype C Infection
    Myron E Essex; Fiscal Year: 2010
    ..This study will also quantify the relative contribution of host genetic factors and non-genetic factors to the current epidemic in southern Africa. ..
  38. DICKSON CHIBANDA; Fiscal Year: 2014
    ..and to estimate the effect of the integrated depression-adherence intervention on antiretroviral adherence, CD4 lymphocyte count, and depression...
  39. Eric J Arts; Fiscal Year: 2016
    ..We propose that the majority of HIV-1 transmitted from donor to recipient is trapped in the mucosal tissue (e.g. cervix) due to lectin binding and other barriers that effectively "keep pathogens out". ..
  40. Risk, Severity and Outcome of Bacterial Pneumonia in an HIV +/- Veteran Cohort
    KRISTINA ANNE CROTHERS; Fiscal Year: 2010
    ..These studies can inform patient care and provide a basis for future studies aimed at preventing and improving outcomes from bacterial pneumonia. ..
  41. Zheng W Chen; Fiscal Year: 2016
    ..III. Determine if HMBPP/IL-2 expansion of V?2V[unreadable]2 T cells can overcome depressed responses of CD4/CD8 T cells and protect against HIV-related TB in SHIV-infected macaques with low CD4 counts. ..
  42. SIMON BYSTRYAK; Fiscal Year: 2014
    ..Advantages of the proposed technology such as the speed, convenience, and low cost of the analysis substantiates our belief that the FTCA will be widely used in clinical practice. ..
  43. Cristian L Achim; Fiscal Year: 2015
    ..As these individuals mature, it will be important to understand the implications of neurocognitive impairment on their future behaviors. ..
  44. Savita Pahwa; Fiscal Year: 2014
    ....
  45. WORKSHOP ON THE ORAL MANIFESTATIONS OF HIV INFECTION
    John Greenspan; Fiscal Year: 2000
    ..abstract_text> ..
  46. Sydney Rosen; Fiscal Year: 2014
    ..Finally, it will help to build the evidence base for "test-and-treat," one of the most innovative ideas currently considered to prevent HIV transmission. ..
  47. Ann Elizabeth Kurth; Fiscal Year: 2015
    ..Partnership with Kenya's national HIV program will allow lessons learned from this study to inform other countries considering how best to address the growing IDU contribution to the HIV epidemic in this high-HIV-burden region. ..
  48. Self-Generation of Prospective Memory in HIV-Infected Methamphetamine Users
    Erica Weber; Fiscal Year: 2013
    ..g., non-adherence) deficits in persons living with HIV infection and addictions. ..
  49. Ha Youn Lee; Fiscal Year: 2016
    ..The proposed work will advance HIV prevention research by providing a reliable assay based on the characteristics of intrahost HIV diversification. ..
  50. SECOND INT1 WORKSHOP-ORAL MANIFESTION OF HIV INFECTION
    John Greenspan; Fiscal Year: 1993
    ....
  51. Closing the gaps in PMTCT program coverage, early infant diagnosis and treatment.
    Mary Ann Davies; Fiscal Year: 2013
    ..Using these data, PMTCT program failures will be regularly and systematically analyzed together with Provincial and Local Departments of Health service managers and providers, with a view to achieving iterative service improvements. ..
  52. Contraception, pregnancy, and HIV-1 risk in African HIV-1 serodiscordant couples
    Jared Baeten; Fiscal Year: 2012
    ....
  53. PS05-085, Surv of HIV/AIDS Related Events Among Persons Not Receiving Care
    BARBARA BOLDEN; Fiscal Year: 2009
    ..abstract_text> ..
  54. Regulation of APOBEC3G enzymatic activity in HIV-infected primary human T cells
    Jaisri R Lingappa; Fiscal Year: 2012
    ..The proposed studies should greatly contribute to our knowledge of how A3G/F functions in primary human cells and will add significantly to our incomplete understanding of A3G/F in infected patients. ..
  55. BRANDON LODGE GUTHRIE; Fiscal Year: 2016
    ....
  56. HIV-1 Fitness and Recombination
    Eric J Arts; Fiscal Year: 2012
    ..Based on strong reviewer encouragement from the last funding period, we will continue our modeling studies with our collaborators, Drs. Thomas Leitner and Alan Perelson at Los Alamos National Laboratories (aim 3). ..
  57. Fungal infections and tolerogenic immunosuppression
    Fernanda Silveira; Fiscal Year: 2009
    ..Therefore, another major aim of the study is to serially collect serum and urine on consecutive transplant recipients with a view to having a "bank" on which to test new diagnostic methodologies. ..
  58. MICHAEL DAVID HUGHES; Fiscal Year: 2014
    ..The ultimate goal is to develop practical approaches that can be readily implemented in HIV and co-infection research and, in doing so, help improve programs for the prevention of transmission and the treatment of HIV-infected people. ..
  59. CHEMOKINES AND HIV REPLICATION IN ALVEOLAR MACROPHAGES
    Michael Coffey; Fiscal Year: 2000
    ..In summary, this proposal will help determine the mechanisms by which HIV replication is regulated by C-C chemokines in AM, and enhance our understanding of and our ability to control HIV infection in the lung. ..
  60. Immune Recovery Following LLME Treated Cell Therapy
    Joanne Filicko; Fiscal Year: 2006
    ..abstract_text> ..
  61. TUAN DINH LE; Fiscal Year: 2014
    ..abstract_text> ..
  62. Impact of HIV-1 Fitness on Disease Progression
    Eric Arts; Fiscal Year: 2001
    ..Competitions between these env pseudotyped HIV-1 clones will then be compared to competitions between two propagated HIV-1 isolates from the same two patient samples. ..
  63. HIV Therapy & Interruption RCT in Resource Poor Clinic
    Luis J Montaner; Fiscal Year: 2010
    ..abstract_text> ..
  64. HIV Therapy & Interruption RCT in Resource Poor Clinic
    Luis Montaner; Fiscal Year: 2004
    ..abstract_text> ..
  65. LPS and Monocyte Activation in HIV Neuropathogenesis
    Dana Gabuzda; Fiscal Year: 2009
    ..The studies will also provide information that could help to identify new potential therapeutic strategies for HIV/AIDS. ..
  66. A lateral flow CD4 counting assay for resource-poor regions
    Michael Lane; Fiscal Year: 2007
    ..unreadable] [unreadable] [unreadable]..
  67. Immunologic Effects of Lactation on HIV infected women
    Grace Aldrovandi; Fiscal Year: 2006
    ..Changes in HIV plasma RNA levels over 12 months of breastfeeding will be compared to baseline levels as well as parameters of T cell turnover and thymopoiesis. ..
  68. ENDODONTIC TREATMENT FOR PERSONS WHO ARE HIV POSITIVE
    David Rosenstein; Fiscal Year: 2001
    ..cellular immunity function will be accurate predictors for endodontic success or failure, and that the CD4 lymphocyte count alone is an inadequate base for making such decisions...
  69. Genomic and immunological comparisons of M africanum and M tuberculosis
    Bouke C de Jong; Fiscal Year: 2010
    ..The proposed research tries to explain why this bacterium, M. africanum, is more common in HIV infected people, and why a new diagnostic test does not work as well in people with this type of tuberculosis. ..